Correction: Cost-Effectiveness of Vedolizumab as a First-Line Advanced Therapy Versus Adalimumab Treatment Sequences for Ulcerative Colitis in Italy [0.03%]
对 vedolizumab 作为溃疡性结肠炎的一线生物制剂疗法与意大利阿达木单抗治疗序列的成本效益研究的更正通知
Jonathan Salcedo,Daniel Hill-McManus,Chloë Hardern et al.
Jonathan Salcedo et al.
Published Erratum
PharmacoEconomics - open. 2025 Aug 19. DOI:10.1007/s41669-025-00596-w 2025
Treatment (as Prevention) Availability and Individuals' Behavior: A Cost-Effectiveness Analysis of Cabotegravir Long-Acting Injectable PrEP [0.03%]
作为预防的治疗可及性与个体行为：卡博特格拉韦长效注射剂作为一种暴露前预防的成本效益分析
J Felipe Montano-Campos,Blythe Adamson
J Felipe Montano-Campos
Background: The US Food and Drug Administration (FDA) has approved long-acting injectable agents for preexposure prophylaxis (PrEP) of human immunodeficiency virus (HIV) infection. These agents are urgently required to en...
Economic Evaluation of Treatment With Trastuzumab Deruxtecan for HER2-Low Advanced or Metastatic Breast Cancer in Previously Treated Patients [0.03%]
治疗HER2低表达晚期或转移性乳腺癌患者的曲妥珠单抗deruxtecan疗法的经济评估
Silvia Fenix-Caballero,Pablo Caleffa-Menendez,Carmen Maria Dominguez-Santana et al.
Silvia Fenix-Caballero et al.
Objectives: This study evaluates the efficiency and budgetary impact of trastuzumab deruxtecan (T-DXd) compared with standard therapy in previously treated HER2-low advanced or metastatic breast cancer, from the perspecti...
Cost-Effectiveness of an Insertable Cardiac Arrhythmia Monitor after Non-ST-Elevation Myocardial Infarction in the UK [0.03%]
英国非ST段抬高型心肌梗死后植入式心脏监测仪的成本效益分析
Amy Dymond,E Barker,N Tsitiridis et al.
Amy Dymond et al.
Background and objectives: Patients surviving a non-ST-elevation myocardial infarction (NSTEMI) have an elevated risk of future major adverse cardiovascular events (MACE), which can be mitigated through long-term cardiac ...
Economic Evaluation of Lecanemab for Early Symptomatic Alzheimer's Disease in South Korea [0.03%]
韩国早期症状性阿尔茨海默病患者使用莱卡奈单抗的经济学评价
Seungyeon Shin,Maryanne Kim,Song Hee Hong
Seungyeon Shin
Background/objectives: Alzheimer's disease (AD) exerts a considerable economic burden on South Korea's aging population. Lecanemab, an amyloid-targeting therapy, has demonstrated efficacy in mitigating cognitive decline i...
Missing Pieces of the Puzzle to Address Market Failures for Antibiotics: Delinked Payment Systems and Insurance Value [0.03%]
应对抗生素市场失灵的缺失环节：解绑支付体系与价值险%HIT2019国际肿瘤创新大会
Neil Hawkins,Adrian Towse,Amanda Adler
Neil Hawkins
Too few companies develop new antibiotics because of the threat of market failure. To address this, a 'delinked' payment, distinct from the usual payment model for drugs, makes payments to manufacturers that do not depend on the volume of a...
Including Productivity as an Element to Reflect Value of the Treatment: A Systematic Review of Published Health Economic Evaluations [0.03%]
系统综述：已发表的卫生经济学评价中包括作为反映治疗效果价值因素的产品ivity的研究
Hiroaki Mamiya,Kittima Wattanakamolkul,Nan Li et al.
Hiroaki Mamiya et al.
Background: Productivity is utilised inconsistently in value assessment and poses methodological and conceptual challenges for estimation. This systematic literature review aims to understand how productivity gain/loss fo...
Cost-Effectiveness of the CADScor System in Low-Risk Patients Presenting to the Emergency Department with Chest Pain [0.03%]
低风险急性冠脉综合征疑似患者急诊胸痛筛查中CADScor系统的成本效益分析
Suzanne J Baron,Serge Korjian,C Michael Gibson et al.
Suzanne J Baron et al.
Background: Studies have shown that up to 13% of patients presenting to the emergency department (ED) with low-risk chest pain receive further cardiac testing beyond an electrocardiogram and serial cardiac enzymes. The CA...
Real-World Analysis of Healthcare Utilization, Treatment Patterns, and Economic Burden in Medicare Beneficiaries with Parkinson's Disease: Implications by Levodopa Formulation and Disease Severity [0.03%]
美国医保受益人的现实世界分析：疾病利用、治疗模式和经济负担（按左旋多巴配方和疾病严重程度划分的帕金森病的含义）
Renée J G Arnold,Winona Tse,Kimberly Martin et al.
Renée J G Arnold et al.
Objective: This study aimed to evaluate healthcare utilization, costs, and treatment patterns of Medicare beneficiaries with Parkinson's disease (PD) treated with different carbidopa-levodopa regimens. ...
Estimation of Lifetime Costs Among Insured Persons with HIV in the United States [0.03%]
美国HIV感染者终生医疗费用估算
Joshua P Cohen,Vamshi Ruthwik Anupindi,Riddhi Doshi et al.
Joshua P Cohen et al.
Background/objective: With recent advances in human immunodeficiency virus (HIV) management and prevention, it is critical to understand the lifetime costs (LTC) of HIV. The objective of the study was to evaluate all-caus...